Roivant Sciences presents a high-risk, high-reward biotech investment defined by a shrinking cash buffer ($1.2B as of 2026Q1, down 82% from $6.5B in 2023Q4) and escalating R&D spending ($202M in 2026Q1, up 67% from 2023Q4). The company's asset-light model and ...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue has collapsed 95% from $28.9M in 2023Q4 to $1.4M in 2026Q1, while operating losses widened to -$366M, reflecting escalating R&D and SG&A costs.
Roivant Sciences is expanding its brepocitinib development program with a new Phase 2b/3 trial in Lichen Planopilaris (LPP), indicating potential growth in its pipeline.
The U.S. FDA has accepted Roivant's New Drug Application for brepocitinib in dermatomyositis and granted Priority Review, targeting a potential launch by Q3 2026.
Positive Phase 3 study results for batoclimab in Thyroid Eye Disease (TED) could drive investor confidence and future revenue streams.
Trailing total returns as of 9/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.33-10.1% vs -$0.30 | $1M-29.9% vs $2M |
Q2 2026 May 20, 2026 | -$0.28+3.5% vs -$0.29 | $3M-26.2% vs $3M |
Q1 2026 Feb 6, 2026 | -$0.24+19.9% vs -$0.30 | $2M-60.6% vs $5M |
Q4 2025 Nov 10, 2025 | -$0.20+36.9% vs -$0.32 | $2M-72.0% vs $6M |
Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis Transcript
Roivant Sciences NASDAQ: ROIV said the U.S. Food and Drug Administration has approved LISRAYA, its once-daily oral therapy for adults with dermatomyositis, and that the drug has already entered commercial launch.
Roivant and partner Priovant Therapeutics on Friday set a list price of $35,000 for a 30-day supply of their newly approved rare disease drug, Lisraya.
The U.S. Food and Drug Administration said on Thursday it approved a treatment from Roivant and partner Priovant Therapeutics for a rare disease, making it the first oral drug for the condition affecting skin and muscles.
Benchmark ROIV against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Roivant Sciences Ltd. (ROIV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $41.48 | $29.97B | -96.47 | -71.57% | -3629.19% | -5.72% | — | |
| $14.72 | $2.22B | -2.15 | — | — | -1328.94% | — | |
| $39.57 | $8.17B | -14.29 | — | -7585.86% | -69.59% | — | |
| $116.47 | $9.58B | -31.56 | -16.72% | -285.41% | -21.5% | — | |
| $352.48 | $9.83B | -26.15 | -100% | — | -34.15% | — | |
| $248.86 | $439.68B | 105.00 | 8.57% | 9.81% | — | — |
Roivant Sciences Ltd. (ROIV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Roivant Sciences Ltd. (ROIV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
May 20, 2026·SEC
Apr 2, 2026·SEC
Get notified when ROIV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Roivant Sciences Ltd. (ROIV) stock FAQ — growth, dividends, profitability & financials explained
Roivant Sciences Ltd. (ROIV) reported $7.5M in revenue for fiscal year 2025. This represents a 89% decrease from $67.7M in 2019.
Roivant Sciences Ltd. (ROIV) saw revenue decline by 71.6% over the past year.
Roivant Sciences Ltd. (ROIV) reported a net loss of $266.2M for fiscal year 2025.
Roivant Sciences Ltd. (ROIV) has a return on equity (ROE) of -5.7%. Negative ROE indicates the company is unprofitable.
Roivant Sciences Ltd. (ROIV) had negative free cash flow of $814.0M in fiscal year 2025, likely due to heavy capital investments.
